Research Analysts Set Expectations for APLS Q2 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Wedbush cut their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a report issued on Wednesday, May 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.50) for the quarter, down from their previous forecast of ($0.37). Wedbush has a "Neutral" rating and a $29.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals' Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.94) EPS, Q1 2026 earnings at ($0.65) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at $0.37 EPS, FY2028 earnings at $1.56 EPS and FY2029 earnings at $2.95 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $149.90 million during the quarter, compared to analysts' expectations of $197.61 million. During the same quarter in the prior year, the business posted ($0.54) earnings per share. The company's revenue was down 3.2% compared to the same quarter last year.

Other research analysts also recently issued reports about the company. Mizuho dropped their target price on Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday. Robert W. Baird cut their price target on Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. Royal Bank of Canada cut their price target on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Scotiabank dropped their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Finally, Cantor Fitzgerald assumed coverage on Apellis Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $44.00 target price on the stock. Nine analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.42.

Apellis Pharmaceuticals Stock Up 6.3%

Shares of NASDAQ:APLS traded up $1.03 on Monday, reaching $17.39. The company had a trading volume of 749,744 shares, compared to its average volume of 2,229,578. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $43.99. The firm's 50 day simple moving average is $20.48 and its 200-day simple moving average is $26.77. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $2.18 billion, a PE ratio of -8.55 and a beta of 0.73.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Granahan Investment Management LLC lifted its holdings in Apellis Pharmaceuticals by 13.8% in the first quarter. Granahan Investment Management LLC now owns 175,696 shares of the company's stock valued at $3,842,000 after acquiring an additional 21,278 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Apellis Pharmaceuticals by 119.6% in the first quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company's stock valued at $89,173,000 after acquiring an additional 2,220,977 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Apellis Pharmaceuticals in the first quarter valued at approximately $3,280,000. ADAR1 Capital Management LLC lifted its holdings in Apellis Pharmaceuticals by 13.3% in the first quarter. ADAR1 Capital Management LLC now owns 17,000 shares of the company's stock valued at $372,000 after acquiring an additional 2,000 shares during the last quarter. Finally, PDT Partners LLC lifted its holdings in Apellis Pharmaceuticals by 41.7% in the first quarter. PDT Partners LLC now owns 195,165 shares of the company's stock valued at $4,268,000 after acquiring an additional 57,471 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,569 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now directly owns 138,730 shares in the company, valued at $3,482,123. The trade was a 3.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.50% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).